Drug-induced acute kidney injury (AKI) frequently develops in hospitalized patients receiving nephrotoxic therapy.

Q1 2026 earnings call recap: record revenue, reiterated guidance, CEO transition, 510(k) pipeline updates & key risks.

WEDNESDAY, April 22, 2026 (HealthDay News) -- The combination of intrawound tobramycin and vancomycin powder is no better than vancomycin powder alone for reducing deep surgical site infection in ...

Please provide your email address to receive an email when new articles are posted on . A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent ...

Antibiotics previously thought to help people with cirrhosis manage the risk of hepatic encephalopathy do not appear to benefit the condition. These antibiotics possibly cause more side effects than ...

TYZAVAN ™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation ...

Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...

Vancomycin-resistant enterococci are a common cause of healthcare-associated infection. A literature review was conducted to understand the current evidence and support nurses and other health ...

Guidelines recommend against use of midline catheters for vancomycin-based outpatient parenteral antimicrobial therapy (OPAT), but evidence supporting the guidance is limited. This retrospective study ...

Please provide your email address to receive an email when new articles are posted on . However, this finding did not reach statistical significance, the researchers noted. “This is the first ...

LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to ...